Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Organisation › Details

Enara Bio Ltd.

Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors. Our internal focus is developing TCR-directed immunotherapies against Dark Antigen targets that are highly prevalent and homogenously expressed across solid tumors. Our partner, Boehringer Ingelheim, is combining multiple Dark Antigens to create off-the-shelf therapeutic cancer vaccines. Based in Oxford, UK, Enara Bio is backed by a strong syndicate of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. *

 

Period Start 2020-06-03 renamed
  Group Enara Bio (Group)
  Predecessor Ervaxx Ltd.
Products Industry cancer vaccine
  Industry 2 EDAPT™ platform (dark antigen identification)
Persons Person Pojasek, Kevin (Ervaxx 201911 CEO)
  Person 2 Ashrafian, Houman (SV Health Investors 201810 Partner)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 1 Robert Robinson Avenue
Oxford Science Park, The Magdalen Centre
  City OX4 4GA Oxford, Oxfordshire
    Address record changed: 2024-10-05
     
Basic data Employees n. a.
     
    * Document for »About Section«: Enara Bio Ltd.. (10/3/24). "Press Release: Enara Bio Raises $32.5 Million Series B Financing to Advance First-in-Class Pipeline of TCR-based Immunotherapies Targeting Novel Dark Antigens". Oxford.
     
   
Record changed: 2024-10-06

Advertisement

Picture Berlin Partner Top News Aignostics Mayo Clinic Pathology 650x200px

More documents for Enara Bio (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x300px




» top